Penn Presbyterian Medical Center

Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5

Retrieved on: 
Tuesday, March 26, 2024
Opus, Retina, Leber congenital amaurosis, University of Pennsylvania, VR, Genetics, LCA5, University, Patient, Ophthalmology, LCA, Penn Presbyterian Medical Center, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., March 26, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first, clinical-stage gene therapy company developing treatments for inherited retinal diseases, today announced that the first cohort has completed dosing in its open-label, dose-escalation Phase 1/2 clinical trial evaluating the subretinal delivery of OPGx-LCA5, an adeno-associated virus 8 (AAV8) vector designed to precisely deliver a functional LCA5 gene to the outer retina in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5).

Key Points: 
  • Based on positive safety and efficacy data from the first cohort of three adult patients, the Company will advance OPGx-LCA5 into the next highest dose.
  • Opus anticipates initiating the next cohort mid-2024.
  • There are also future plans to expand the study population to include subjects 13 years or older.
  • “Based on these early clinical data, we’re excited for the potential of OPGx-LCA5 to transform the lives of patients affected by LCA5,” said Ben Yerxa, Ph.D., chief executive officer of Opus.

Crowell & Moring International Names Geralyn Ritter New CEO

Retrieved on: 
Monday, February 5, 2024
Mother, Mortality, ESG, Senior, MENA, Penn Presbyterian Medical Center, Ambassador, Sanford School, Government, Sustainability, Politics, Duke University, Retirement, Patient, Social responsibility, Stanford Law School, Corporate Affairs, Corporation, Lawyer, Global health, Woman, CMI, Corporate responsibility, Assistant, Public policy, Merck & Co., Health equity, Business, Pharmacy, Management

WASHINGTON, Feb. 5, 2024 /PRNewswire/ -- Crowell & Moring International LLC (CMI) has named Geralyn Ritter, a seasoned and highly regarded global health care and public policy leader, as president and CEO.

Key Points: 
  • WASHINGTON, Feb. 5, 2024 /PRNewswire/ -- Crowell & Moring International LLC (CMI) has named Geralyn Ritter , a seasoned and highly regarded global health care and public policy leader, as president and CEO.
  • Ritter brings more than 25 years of diverse business, legal, and government experience to her new role, with particular depth in pharmaceuticals, health care, international trade, environmental, social and corporate governance (ESG), and global public policy.
  • Ritter takes the mantle from former Ambassador Robert Holleyman , who has led CMI for the past seven years.
  • Ritter earned her bachelor's degree from Duke University, her master's degree from the Johns Hopkins School of Advanced International Studies, and her law degree from Stanford Law School.

Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)

Retrieved on: 
Monday, November 27, 2023
Penn Presbyterian Medical Center, Associate, Hospital, Disease, Research, University, Standard of care, Patient, Medical device

"PEERLESS II is challenging the most commonly administered first-line therapy for PE around the world,” said Dr. Matthai.

Key Points: 
  • "PEERLESS II is challenging the most commonly administered first-line therapy for PE around the world,” said Dr. Matthai.
  • PEERLESS II is the largest study of its kind and will include up to 1,200 randomized patients at up to 100 global centers.
  • Thank you to the PEERLESS II Steering Committee and clinical staff for helping us get the first patient enrolled."
  • "Inari is actively enrolling three RCTs: PEERLESS, PEERLESS II and DEFIANCE, demonstrating our relentless commitment to guideline-changing research aimed at ultimately improving patient outcomes,” said Dr. Thomas Tu, Inari’s Chief Medical Officer.

Oxford Biodynamics Announces US Launch of its 94% Accurate EpiSwitch® Prostate Screening Blood Test to Men With Prostate Cancer Risk

Retrieved on: 
Tuesday, September 26, 2023
Oncology, Health, Medical Devices, Health Technology, Other Science, Science, Biotechnology, PROMIS, Journal of Clinical Oncology, United States National Library of Medicine, Prostate, LDT, PMID, BJU International, AIM, National Prostate Health Month, University, Prostate cancer, Abner Doble, Hospital, TRUS, Section, Cancer, UK2, OBD, Large intestine, Mortality, Lung, Penn Presbyterian Medical Center, Protection, MRI, Journal, Patient, Risk, Medicine, BMJ, PSE, Movember, PMCID, NHS, Erectile dysfunction, Death, PSA, News, Biopsy, Dairy, Medical imaging, Urology, Lancet

The current blood screening test, the PSA test, is only 55% accurate, and is considered an unreliable test by many doctors, including the NHS in the UK2.

Key Points: 
  • The current blood screening test, the PSA test, is only 55% accurate, and is considered an unreliable test by many doctors, including the NHS in the UK2.
  • It feels wholly appropriate that the early launch of the test coincides with Prostate Cancer Awareness month," said Dr Jon Burrows, OBD's Chief Executive Officer.
  • Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication, Journal of Clinical Oncology [online], 28:15.
  • Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.

Medical Simulation Market to grow by USD 1.99 billion from 2022 to 2027, North America to account for 45% of market growth- Technavio

Retrieved on: 
Thursday, September 21, 2023
Approximation error, Telehealth, Medicine, Clinical data management, Life, Teaching, St. Joseph's Hospital, Biotechnology, FREE, USD, Penn Presbyterian Medical Center, Organization, MHealth, Patient, EHR, Physician, Risk, Patient safety, ROW, Growth, Diagnosis, AI, Research, Nursing, Medical device, Retail, Pharmaceutical industry, Hospital, Pennsylvania Hospital, Geography

NEW YORK, Sept. 20, 2023 /PRNewswire/ --The medical simulation market is expected to grow by USD 1.99 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Sept. 20, 2023 /PRNewswire/ --The medical simulation market is expected to grow by USD 1.99 billion from 2022 to 2027.
  • In addition, the momentum of the market will progress at a CAGR of 15.45% during the forecast period, according to Technavio Research.
  • North America is estimated to contribute 45% to the growth of the global market during the forecast period.
  • The presence of major players in the region is expected to drive the growth of the medical simulation market in the region.

Aquedeon Medical, Inc. Receives FDA IDE Approval for the Duett Vascular Graft System

Retrieved on: 
Wednesday, August 23, 2023
Surgeon, University, Clinical trial, Federal, Thoracic aortic aneurysm, Social Democratic Federation (United States), Penn Presbyterian Medical Center, Cardiopulmonary bypass, Silicon, Patient, Cardiac surgery, Risk, Principal, IDE, FDA, Dentistry

The procedure often requires 30-45 minutes of surgical time to complete anastomoses where the cardiothoracic surgeon sutures each individual native branch vessel to the surgical graft.

Key Points: 
  • The procedure often requires 30-45 minutes of surgical time to complete anastomoses where the cardiothoracic surgeon sutures each individual native branch vessel to the surgical graft.
  • The Duett Vascular Graft System was uniquely designed to standardize and simplify open surgical thoracic aortic procedures with the goal of providing cardiothoracic surgeons a means to treat the target vessels effectively and efficiently.
  • Dr. Szeto also highlighted his longstanding involvement with the Duett Vascular Graft System's evolution, since the company's inception, and expressed enthusiasm about participating in the imminent clinical trial.
  • "The Duett Vascular Graft System has been developed in collaboration with leading cardiothoracic surgeon and the device is aimed at helping to address the complexities and intricacies of thoracic aortic surgeries.

PENN MEDICINE TO STOP ACTIVELY PARTICIPATING IN U.S. NEWS & WORLD REPORT "BEST HOSPITALS" RANKINGS

Retrieved on: 
Monday, June 26, 2023
Vaccine, American Hospital Association, Infection, Medical school, Telehealth, University of Pennsylvania Health System, Perelman School of Medicine at the University of Pennsylvania, Hospital of the University of Pennsylvania, University, Education, Centers for Medicare & Medicaid Services, AUC, U.S. News & World Report Best Hospitals Rankings, Hospital, COVID-19, Raymond, Cancer, Biomedical Research, Roll, Research, Medicine, We, Element, Penn Medicine Princeton Medical Center, Penn, U.S. News & World Report, Penn Presbyterian Medical Center, Bangladesh Technical Education Board, Messenger, Medicare, CAR, NYU Annual Survey of American Law, Home, Patient, Susquehanna River, Faculty, Penns, Health, News, Pharmaceutical industry, Pennsylvania Hospital, MD

Modern medicine goes far beyond hospital walls. Today's health systems provide primary care along with advanced care--from surgeries to cancer treatment to kidney dialysis--in outpatient facilities, in patients' homes, and through virtual platforms or remote monitoring. Although the Hospitals of the University of Pennsylvania-Penn Presbyterian has been named to the "Best Hospitals" Honor Roll of top 20 hospitals for the past 16 consecutive years and Penn Medicine's regional hospitals are ranked among the best in the health system's service area, its leaders say the rankings represent an outdated view of health care, failing to capture the full breadth of "care everywhere" services.

Key Points: 
  • The U.S. News & World Report "Best Hospitals" rankings are based solely on inpatient hospital care of those insured by Medicare.
  • While U.S. News & World Report may continue to rank Penn Medicine hospitals, the health system will cease active participation in the process or results.
  • Penn Medicine will also discontinue any promotion of its position on the "Honor Roll," specialty rankings, or any other rankings content, and it will stop purchasing the U.S. News & World Report badges required to publicize the rankings.
  • Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Volta Medical Announces FDA Clearance of Volta AF-Xplorer™ Software to Simplify Complex Atrial Fibrillation Procedures

Retrieved on: 
Thursday, May 18, 2023
Heart Rhythm Society, Database, CT, Ohio State University, Freedom, HRS, Workflow, Atrial fibrillation, Missing Link, Atrial tachycardia, Patient, Physician, Penn Presbyterian Medical Center, Artificial intelligence, Poster, E-GMS, AI, AF, Arrhythmia, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Software, Medical device, Medical imaging, DRS

MARSEILLE, France, May 18, 2023 (GLOBE NEWSWIRE) -- Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists in treating complex cardiac arrhythmias such as atrial fibrillation (AF), today announced that the U.S. Food and Drug Administration (FDA) has cleared Volta AF-Xplorer™, an AI companion designed for the assessment of complex AF and atrial tachycardia (AT) procedures. The company will showcase the latest solution at the 44th annual Heart Rhythm 2023, in New Orleans, LA, and virtually, from May 19-21.

Key Points: 
  • “There is a critical need for new ways to quickly and accurately identify abnormal electrograms (EGMs) for cardiac electrophysiologists to optimize their ablation strategy.
  • Volta AF-Xplorer offers a tailored and intuitive workflow while allowing physicians to use their preferred mapping system and catheter,” said Theophile Mohr-Durdez, Volta Medical CEO and co-founder.
  • The software upgrade features an enhanced integration with Abbott Laboratories’ EnSite X mapping system, providing improved workflow due to automated Volta “regions of interest” tagging capabilities.
  • The Volta Medical booth (#1340) will feature a demonstration of the Volta AF-Xplorer software.

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks

Retrieved on: 
Monday, March 27, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Disability studies, Tissue, Heart, Sensory loss, US Foods, Central nervous system, University, CV, Heart failure, Metabolism, Serum, Diabetic neuropathy, Heredity, Pancreas, Ageing, Quality of life, American Academy, Department of Neurology, Xuanwu hospital, Biopharmaceutical, AstraZeneca, Central nervous system disease, Sympathetic nervous system, LICA, Inotersen, Penn Presbyterian Medical Center, Ionis, Muscle weakness, TTR, ATTR, Patient, Orphan, Cardiomyopathy, Diagnosis, Growth, Phase, Polyneuropathy, Death, Safety, Perelman School of Medicine at the University of Pennsylvania, Disease, Medical imaging, Pharmaceutical industry, Science, Neurology

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks.

Key Points: 
  • Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks.
  • The trial also met its third co-primary endpoint demonstrating a statistically significant reduction in serum TTR concentration versus an external placebo group.
  • Eplontersen continued to demonstrate a safety and tolerability profile consistent with that observed at 35 weeks.
  • We are encouraged by the sustained benefit demonstrated by eplontersen and what a self-administered treatment could mean for patients and families affected by ATTRv-PN.

Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN

Retrieved on: 
Monday, March 27, 2023
Norfolk, Disability studies, University, Heart failure, Serum, International Symposium on Endovascular Therapy, AAN, Diabetic neuropathy, Quality of life, American Academy, IONS, Biopharmaceutical, Department of Neurology, Xuanwu hospital, AstraZeneca, Penn Presbyterian Medical Center, TTR, Patient, PDUFA, Orphan, Cardiomyopathy, Diagnosis, Polyneuropathy, American Academy of Neurology, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neurology, Food, Safety, Perelman School of Medicine at the University of Pennsylvania, Pharmaceutical industry, Science, Ionis, Amyloidosis

(Nasdaq: IONS) today announced positive topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), a debilitating and potentially fatal disease that leads to peripheral nerve damage and motor disability.

Key Points: 
  • (Nasdaq: IONS) today announced positive topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), a debilitating and potentially fatal disease that leads to peripheral nerve damage and motor disability.
  • The study also met its third co-primary endpoint demonstrating a statistically significant reduction in serum TTR concentration versus an external placebo group.
  • "This builds on the favorable 35-week results, which first demonstrated eplontersen's potential to significantly improve outcomes in this underserved population."
  • "Together with our partner AstraZeneca, we look forward to sharing detailed results from this study at the upcoming American Academy of Neurology Annual Meeting."